ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elegrobart

Also written as “VRDN-003” and “ZL-1109 (VRDN-003)”.

Its studies are mostly in Graves Ophthalmopathy, led by 2 companies.

Drug pageElegrobart: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 1, 20245 company-led studies, 4 open or runningNext primary completion: Mar 14, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viridian Therapeuticsits history only43 open or runningphase 3since Oct 1, 2024Oct 1, 2024none ahead
Zai Labits history only11 open or runningphase 3since Oct 1, 2025Oct 1, 2025Mar 14, 2027phase 3 · NCT07211776

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 1, 2024First studies: 2 phase 3 studies in Graves OphthalmopathyNew to Viridian TherapeuticsViridian Therapeutics · NCT06625411, NCT06625398
  2. Jan 27, 2025Phase 3 study in Graves OphthalmopathyViridian Therapeutics · NCT06812325 · 320 enrolled · United States, France, Germany and more
  3. Feb 13, 2025Named elegrobartINNProposed as its International Nonproprietary Name in WHO's List 132 · before, VRDN-003
  4. Aug 7, 2025Phase 3 study in Graves OphthalmopathyViridian Therapeutics · NCT07155668 · 87 enrolled · United States
  5. Oct 1, 2025Zai Lab’s first study: phase 3 study in Graves OphthalmopathyNew to Zai LabZai Lab · NCT07211776 · 108 enrolled · China

Ahead

  1. Mar 14, 2027Primary completion: phase 3 study in Graves OphthalmopathyZai Lab · NCT07211776

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07211776Graves Ophthalmopathy · China3Active, not recruitingZai LabMar 14, 2027108
NCT07155668Graves Ophthalmopathy · United States3CompletedViridian TherapeuticsMay 28, 202687
NCT06812325Graves Ophthalmopathy · United States, France, Germany and more3Active, not recruitingViridian TherapeuticsApr 22, 2026320
NCT06625411Graves Ophthalmopathy · United States, Germany, Hungary and more3Active, not recruitingViridian TherapeuticsFeb 12, 2026132
NCT06625398Graves Ophthalmopathy · United States, Germany, Hungary and more3Active, not recruitingViridian TherapeuticsMar 4, 2026204

How it is read

Names in the registry

  • “VRDN-003”, 4 entries
  • “ZL-1109 (VRDN-003)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.